LOCAL PROVIDER DIRECTORY
Find a dentist
Search by name or specialty, then choose a city and region or enter a ZIP / postal code.
Choose a location to keep your results local.
Local Health Alerts
Long COVID in 2026: Fatigue, Prevention, and Higher-Risk Groups
New CDC guidance and fresh research reinforce the same core message: long COVID can follow even a mild infection, normal tests do not rule it out, and the best proven way to lower risk is still reducing the chances of severe COVID-19. Early…
FDA’s rare-disease approval push could widen access for ultra-rare therapies
The FDA says it wants to make room for individualized treatments in ultra-rare diseases without lowering the bar for evidence. A new draft framework, plus several 2026 approvals, shows how regulators are trying to balance flexibility with proof that a therapy targets the…
FDA’s New Pregnancy-Safety Guidance Could Improve Medicine Data
The FDA has finalized new guidance on collecting pregnancy-safety data after a drug or biologic is approved. The change will not rewrite labels overnight, but it could strengthen the evidence doctors and patients rely on when deciding whether medicine is needed during pregnancy.
Earlier LDL lowering for primary prevention: what new evidence changes
New 2026 research adds momentum to earlier LDL lowering for people without prior heart attack or stroke. But the basics have not changed: healthy habits, blood pressure control, cholesterol screening, and statins remain the mainstay for most primary prevention decisions.
Should breast screening depend on risk instead of age?
A large randomized trial suggests breast cancer screening can be tailored by risk without missing more advanced cancers compared with standard screening. But U.S. guidance has not broadly shifted yet, and experts still see important limits in the evidence.
FDA’s real-time clinical trial push could change how results are reported
The FDA is testing a faster way to view some trial data as studies are running while also pressing sponsors to catch up on overdue results reports. The big takeaway for readers: this is a change in transparency and timing, not proof that…
FDA Pregnancy-Safety Guidance Aims to Improve Drug Data
The FDA has finalized guidance meant to help sponsors collect better pregnancy safety data after a drug or biologic is approved. The goal is not to label any one medicine safer or riskier on its own, but to improve the evidence doctors and…
FDA guidance aims to improve pregnancy safety data after approval
The FDA has finalized guidance meant to help drug and biologic makers study pregnancy safety after a product is approved. For patients, the practical message is simple: this does not change prescriptions by itself, and it does not prove a medicine is safe…
Long COVID in 2026: CDC says normal tests don’t rule it out
CDC’s updated Long COVID guidance keeps the focus on symptoms, function, and follow-up care. The key takeaway for readers is simple: a normal lab workup does not automatically rule out Long COVID.
FDA’s Menkes Approval Raises Newborn Screening Questions
A new FDA-approved treatment for Menkes disease raises the stakes for early diagnosis. The hard part now is whether newborn screening systems can find ultra-rare disorders fast enough, accurately enough, and fairly enough to help babies in time.
Pregnancy RSV shots: what the newest CDC data say about uptake, timing, and safety
CDC’s latest coverage dashboard shows that many pregnant people still have not chosen an RSV prevention strategy. The practical question is still timing: maternal Abrysvo in late pregnancy or infant nirsevimab after birth.
New blood pressure monitoring evidence may catch hidden hypertension earlier
A new 2026 review is putting more attention on blood pressure checks done at home and other settings outside the doctor’s office. Those readings can sometimes spot masked high blood pressure or rule out a one-time office spike, which may help prevention efforts…